Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, ...
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily serving China, with its operations headquartered in Ji’An, China. The company’s core business combines (1) in-house manufacturing of traditional Chinese medicine (TCM)–derived products and (2) commercial distribution and sales of a broader catalog of third-party healthcare items. Its product and ...Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily serving China, with its operations headquartered in Ji’An, China. The company’s core business combines (1) in-house manufacturing of traditional Chinese medicine (TCM)–derived products and (2) commercial distribution and sales of a broader catalog of third-party healthcare items. Its product and service scope is positioned around chronic health management for elderly patients and common seasonal needs such as cold and flu symptoms, reflecting a practical, customer-facing approach to healthcare consumption in its domestic market.
From a product perspective, UPC emphasizes remedies derived from traditional Chinese medicine, which typically involve sourcing botanicals and other raw materials, processing them into standardized medicinal forms, and packaging them for sale. In addition to its own manufactured offerings, the company functions as a distributor and vendor for biomedical drugs, medical instruments, TCM “pieces” (raw ingredients), and dietary supplements—giving it multiple revenue streams across both manufactured and agency/distribution categories. This hybrid model can improve portfolio breadth: manufacturing supports differentiation and brand/clinical familiarity, while distribution can help reduce product development timelines and stabilize assortment availability.
Cost structure and business operations for a TCM-leaning pharmaceutical distributor/manufacturer generally revolve around raw material procurement (including seasonal supply risk), conversion/processing costs, regulatory compliance, warehousing and logistics, and sales/channel expenses. Inventory and working-capital management can be material—consistent with the company’s reported balance-sheet indicators showing sizable working capital and liquidity ratios. The company also carries operating leverage related to marketing and general & administrative expenses, while typical pharmaceutical gross margins can be influenced by product mix (manufactured products vs. distributed goods), pricing dynamics, and promotional activities.
Financially, the provided snapshot metrics indicate profitability pressure in the most recent trailing period (e.g., negative operating, EBIT, and net profit margins, and negative free cash flow). This suggests the company may be investing in growth, absorbing operating costs, or experiencing margin compression. Even so, liquidity measures such as a relatively strong current ratio point to an ability to fund operations in the near term.
Key people leadership is led by CEO & Chairman Gang Lai, with CFO and director roles reported for Lin Yang and other senior operational leadership including Baochang Liu (Chief Operating Officer). UPC is also described as a subsidiary of Sununion Holding Group Limited. Looking at the company’s strategic intent, leadership commentary and corporate positioning indicate continued efforts to expand its footprint—potentially through acquisitions, expanded distribution coverage, and broader access to healthcare customers such as pharmaceutical companies, hospitals, clinics, and major drugstore chains.
Overall, UPC’s story is that of a China-focused specialty pharma/distribution company rooted in TCM derivatives, leveraging both manufacturing capabilities and distribution channels to build a diversified healthcare portfolio. The main execution themes to watch include margin recovery, cash-flow improvement, supply-chain stability for raw ingredients, regulatory execution, and effectiveness in expanding distribution partners and customer reach.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$17.9M
-22.4%
+3.8%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-3.7M
+57.9%
-301.4%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+35.3%
+33.8%
-0.9%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-16.3%
+53.1%
-145.3%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-20.6%
+45.8%
-286.8%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-5.4M
+45.3%
+40.8%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-30.2%
+29.5%
+42.9%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
16.5%
-6.1%
+4.1%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
4.07x
+60.1%
-0.6%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
